Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record.

Clinical Implications of the Pharmacology of Sertraline

WARRINGTON, S. J. · 1991 · International Clinical Psychopharmacology

Abstract

Sertraline is slowly absorbed after oral administration, with peak plasma concentrations at 6-8 h. Plasma concentrations are linearly related to dose. The elimination half-life is about 32 h; metabolism is by demethylation to an inactive metabolite. Once-daily dosing is recommended, with steady state being reached after about 7 days. The kinetics of sertraline in the elderly and in patients with renal impairment are similar to those in young healthy female volunteers. In young male volunteers, peak plasma concentrations were lower, and elimination half-life shorter, than in elderly men or both groups of women. Nevertheless, no reduction in dosage is recommended for these groups. Sertraline is highly active in animal models of depression, and administration of the drug to healthy human beings causes a selective, dose-related inhibition of 5-hydroxytryptamine (5-HT) uptake into blood platelets. Single doses of sertraline in volunteers caused changes in the quantitative pharmaco-electroencephalogram suggesting antidepressant and anxiolytic actions, with sedative potential evident only at doses of 200 mg or more. Sertraline does not impair psychomotor performance, including simulated car driving, and overall seems neither stimulating nor sedating: an increase in critical flicker fusion threshold suggests a slight alerting effect, whereas subjective tests indicate an increase in perceived sedation at doses of 100 mg or more. No potentiation of the effects of ethanol has been noted in either young or elderly subjects. No adverse effects on the electrocardiogram, blood pressure, or systolic time intervals have been detected, and sertraline lacks anticholinergic action. These studies imply a low probability of adverse central nervous and cardiovascular effects. Sertraline is probably a weak inducer of hepatic microsomal enzyme activity. Sertraline does not affect the clearance of lithium but there may be a pharmacodynamic interaction which leads to increased tremor when the drugs are given together. No clinically relevant effects were noted in the interaction studies with digoxin, atenolol and diazepam. The pharmacokinetics and pharmacodynamics of sertraline are generally favourable. However, caution is needed when sertraline is given to patients receiving lithium or drugs with a low therapeutic ratio, such as corticosteroids, oral hypoglycaemic agents, and warfarin.

Overview

Integrity signals

Registry

Crossref · 10.1097/00004850-199112002-00004

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 119

Metadata

Authors
WARRINGTON, S. J.
Corresponding author
WARRINGTON, S. J.
Venue
International Clinical Psychopharmacology
Published
1991-12
Volume
6
Pages
11-22
ISSN
0268-1315 (ISSN-L)
OpenAlex
W2057710656
Cited by
119
References
0
Citations by year
2026: 4 · 2024: 4 · 2023: 1 · 2022: 3 · 2020: 2 · 2019: 3 · 2018: 4 · 2017: 2 · 2016: 2 · 2015: 2 · 2014: 3 · 2013: 2 · 2012: 6
FWCI
6.13
Type
journal article
Language
en
Open access
closed
Locations
  • International Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
sertraline, pharmacokinetics, pharmacodynamics, selective serotonin reuptake inhibitors, antidepressants, 5-hydroxytryptamine uptake, plasma concentration, elimination half-life, drug interactions, lithium, hepatic enzyme induction, sedation, elderly patients, renal dysfunction, depression
MeSH terms
Adult, Aged, Antidepressive Agents, Blood Platelets, Depressive Disorder, Dose-Response Relationship, Drug, Drug Interactions, Female, Humans, Male, Metabolic Clearance Rate, Middle Aged, Neurologic Examination, Psychomotor Performance, Serotonin, 1-Naphthylamine, Sertraline

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Implications of the Pharmacology of Sertraline. https://app.cochat.ai/papers/10.1097/00004850-199112002-00004
The paper
WARRINGTON, S. J. (1991). Clinical Implications of the Pharmacology of Sertraline. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-199112002-00004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.